RQ Biotechnology, a company focused on making instant immunity a reality for vulnerable people, has closed a $115.0M Series A funding round. The substantial capital infusion will support its mission to develop potent, broad-spectrum monoclonal antibodies (mAbs) for infectious diseases where traditional vaccines may not be effective.
The passive immunization discovery company, which partners with pharmaceutical firms to bring its antibodies to market, secured investment from a syndicate including EQT Life Sciences, Frazier Life Sciences, Forbion, Monograph Capital, Wellington Management, and LifeArc Ventures. RQ Bio aims to provide instant and long-lasting protection against current and future viral infections.












